Viatris (VTRS)

Common Shares

Sell: $10.04|Buy: $10.08|Change: 0.12 (1.20%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Open

$10.08

Previous close

$9.98

Trade high

$10.20

Volume

6,150,700

Year high

$13.55

Year low

$6.85

Dividend yield

4.8%

Market capitalisation

$11.78 bn

P/E ratio

236.20

ISIN

US92556V1061

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Share price

Dividends

	Previous	Latest
Record date	23/05/2025	22/08/2025
Ex-dividend date	23/05/2025	22/08/2025
Payment date	16/06/2025	15/09/2025
Amount	$0.12	$0.12

Performance 15/10/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Viatris	+ 0.50
More...

Company profile

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.